BioSpace News Archive

- Initiated clinical research of investigational monoclonal antibodies BRII-196 and BRII-198 in combination for the treatment of COVID-19 in collaboration with the NIH-NIAID - Continues to rapidly advance the development of potential therapeutics for the mitigation of serious infectious disease threats by HBV, multi-drug resistant gram-negative bacteria, and HIV - Continues to advance CNS programs with IND for BRII-296 planned for January 2021

As physicians and health care professionals from around the United States begin to receive the COVID-19 vaccine, the College of American Pathologists urged pathologists and laboratory professionals to receive access during the initial phase of the vaccine’s distribution as they continue their heroic efforts against the pandemic.

Following the arrival of multiple ultralow freezers, extensive training of its team members and a successful day of mock distribution and administration, Novant Health inoculated its first front-line health care workers , using the Pfizer-BioNTech COVID-19 vaccine.

PRA’s remote patient monitoring (RPM) solution now offers a suite of COVID-19 tools – diagnostic testing, clinical monitoring, and symptom reporting and management functionality

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL)

Conformis, Inc. announced the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. The Company previously announced 510 clearance by the U.S. Food and Drug Administration for the Cordera™ Hip System on September 29, 2020, and Cordera™ Match represents one of multiple planned product extensions featuring the proven Cordera™ Hip System.

BIOMODEX®, a pioneering digital health company that offers a unique and enhanced 3D printed solution for patient-specific rehearsal and physician training, today announced the company’s EVIAS™ (EndoVascular Intracranial Aneurysm System) solution was the focus of a presentation at SFNR 2020.

Amgen (NASDAQ: AMGN) and LabCentral today announced that Octagon Therapeutics and Seranova Bio have each won an Amgen Golden Ticket to LabCentral, Cambridge’s premier launchpad for high-potential life sciences and biotech start-ups.